Bone morbidity in chronic myeloproliferative neoplasms

References

• Swerdlow SH CE, Harris NL, et al. editors. WHO Classification of tumours of the Haematopoietic and Lymphoid Tissues. IARC; Lyon, France: 2008
   Google Scholar
• Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22(1):14-22
   PubMed Web of Science ®Google Scholar
• Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood 2011;118(25):6515-20
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? Blood 2012;119(14):3219-25
   PubMed Web of Science ®Google Scholar
• Lacativa PG, Farias ML. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol 2010;54(2):123-32
   PubMedGoogle Scholar
• Panteli KE, Hatzimichael EC, Bouranta PK, et al. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br J Haematol 2005;130(5):709-15
   PubMed Web of Science ®Google Scholar
• Farmer S, Horvath-Puho E, Vestergaard H, et al. Chronic myeloproliferative neoplasms and risk of osteoporotic fractures; a nationwide population-based cohort study. Br J Haematol 2013;163(5):603-10
   PubMed Web of Science ®Google Scholar
• van der Veer E, van der Goot W, de Monchy JG, et al. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 2012;67(3):431-8
   PubMed Web of Science ®Google Scholar
• Andersen CL, Kristensen TK, Severinsen MT, et al. Systemic mastocytosis–a systematic review. Danish medical journal 2012;59(3):A4397
   Web of Science ®Google Scholar
• Metcalfe DD. Mast cells and mastocytosis. Blood 2008;112(4):946-56
   PubMed Web of Science ®Google Scholar
• Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37(6):435-53
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Boucher W, Spear K. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 2002;128(4):344-50
   PubMed Web of Science ®Google Scholar
• Brockow K, Akin C, Huber M, Metcalfe DD. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 2005;115(2):216-23
   PubMed Web of Science ®Google Scholar
• Seitz S, Barvencik F, Koehne T, et al. Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis. Osteoporosis Int 2013;24(8):2325-34
   PubMed Web of Science ®Google Scholar
• Guillaume N, Desoutter J, Chandesris O, et al. Bone complications of mastocytosis: a link between clinical and biological characteristics. Am J Med 2013;126(1):75 e71-7
   Web of Science ®Google Scholar
• Cundy T, Beneton MN, Darby AJ, et al. Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption. Bone 1987;8(3):149-55
   PubMed Web of Science ®Google Scholar
• Johansson C, Roupe G, Lindstedt G, Mellstrom D. Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 1996;25(1):1-7
   PubMed Web of Science ®Google Scholar
• Barete S, Assous N, de Gennes C, et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010;69(10):1838-41
   PubMed Web of Science ®Google Scholar
• Rossini M, Zanotti R, Bonadonna P, et al. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 2011;49(4):880-5
   PubMed Web of Science ®Google Scholar
• Broesby-Olsen S, Kristensen T, Vestergaard H, et al. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis. J Allergy Clin Immunol 2013;132(3):723-8
   PubMed Web of Science ®Google Scholar
• Farmer S, Hermann AP, Vestergaard H. Severe osteoporosis in a patient with polycythaemia vera. Ugeskrift for laeger 2014;176:29
   PubMedGoogle Scholar
• Roberts BE, Woods CG, Miles DW, Paterson CR. Bone changes in polycythaemia vera and myelosclerosis. J Clin Pathol 1969;22(6):696-700
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM. The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Curr Hematol malign Rep 2009;4(1):33-40
   PubMedGoogle Scholar
• Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342(17):1255-65
   PubMed Web of Science ®Google Scholar
• Poulsen LW, Melsen F, Bendix K. A histomorphometric study of haematological disorders with respect to marrow fibrosis and osteosclerosis. APMIS 1998;106(4):495-9
   PubMed Web of Science ®Google Scholar
• Schmidt A, Blanchet O, Dib M, et al. Bone changes in myelofibrosis with myeloid metaplasia: a histomorphometric and microcomputed tomographic study. Eur J Haematol 2007;78(6):500-9
   PubMed Web of Science ®Google Scholar
• Guermazi A, de Kerviler E, Cazals-Hatem D, et al. Imaging findings in patients with myelofibrosis. Eur Radiol 1999;9(7):1366-75
   PubMed Web of Science ®Google Scholar
• Mellibovsky L, Marinoso ML, Cervantes F, et al. Relationship among densitometry, bone histomorphometry, and histologic stage in idiopathic myelofibrosis. Bone 2004;34(2):330-5
   PubMed Web of Science ®Google Scholar
• Diamond T, Smith A, Schnier R, Manoharan A. Syndrome of myelofibrosis and osteosclerosis: a series of case reports and review of the literature. Bone 2002;30(3):498-501
   PubMed Web of Science ®Google Scholar
• Farmer S, Vestergaard H, Hansen S, et al. Bone geometry, bone mineral density, and micro-architecture in patients with myelofibrosis: a cross-sectional study using DXA, HR-pQCT, and bone turnover markers. International journal of hematology 2015
   Web of Science ®Google Scholar
• Barosi G, Costa A, Liberato LN, et al. Serum procollagen-III-peptide level correlates with disease activity in myelofibrosis with myeloid metaplasia. Br J Haematol 1989;72(1):16-20
   PubMed Web of Science ®Google Scholar
• Jensen MK, Riisbro R, Holten-Andersen MN, et al. Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism. Eur J Haematol 2003;71(4):276-82
   PubMed Web of Science ®Google Scholar
• Hasselbalch H, Junker P, Lisse I, et al. Serum markers for type IV collagen and type III procollagen in the myelofibrosis-osteomyelosclerosis syndrome and other chronic myeloproliferative disorders. Am J Hematol 1986;23(2):101-11
   PubMed Web of Science ®Google Scholar
• Schabel SI, Tyminski L, Holland RD, Rittenberg GM. The skeletal manifestations of chronic myelogenous leukemia. Skeletal Radiol 1980;5(3):145-9
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O’Brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data. Cancer 2003;98(12):2636-42
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29(6):761-70
   PubMed Web of Science ®Google Scholar
• Michiels JJ, Berneman Z, Schroyens W, et al. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 2006;32(6):589-604
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350(2):114-24
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Steinberg TH, Schwarz P, Jorgensen NR. Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture. Int J Cardiol 2012;160(1):36-40
   PubMed Web of Science ®Google Scholar
• Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med 2006;260(1):76-87
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New Engl J Med 1995;332(17):1132-6
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013;121(10):1720-8
   PubMed Web of Science ®Google Scholar
• Vannucchi AM. How I treat polycythemia vera. Blood 2014;124(22):3212-20
   PubMed Web of Science ®Google Scholar
• Bonifazi F, de Vivo A, Rosti G, et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98(10):3074-81
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, Larsen TS, Riley CH, et al. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives. Curr Drug Targets 2011;12(3):392-419
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008;112(8):3065-72
   PubMed Web of Science ®Google Scholar
• Ocias LF, Holmstrom MO, Riley CH, et al. [Status and perspectives on chronic myeloproliferative neoplasm treatment]. Ugeskrift for laeger 2015;177:19
   Google Scholar
• Kusec R, Kusec V, Gisslinger B, et al. Bone metabolism during interferon-alpha treatment of essential thrombocythemia. Wien Klin Wochenschr 2004;116(1-2):37-41
   PubMed Web of Science ®Google Scholar
• Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol 2005;114(1):26-40
   PubMed Web of Science ®Google Scholar
• Weide R, Ehlenz K, Lorenz W, et al. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol 1996;72(1):41-3
   PubMed Web of Science ®Google Scholar
• Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354(19):2006-13
   PubMed Web of Science ®Google Scholar
• Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008;111(5):2538-47
   PubMed Web of Science ®Google Scholar
• O’Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009;94(4):1131-6
   PubMed Web of Science ®Google Scholar
• Jonsson S, Standal T, Olsson B, et al. Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib. Am J Hematol 2012;87(5):550-2
   PubMed Web of Science ®Google Scholar
• O’Sullivan S, Horne A, Wattie D, et al. Bone metabolism during long-term treatment with imatinib. Leukemia & lymphoma 2013;54(8):1783-5
   PubMed Web of Science ®Google Scholar
• Deisseroth A, Kaminskas E, Grillo J, et al. U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res 2012;18(12):3212-17
   PubMed Web of Science ®Google Scholar
• Santos FP, Verstovsek S. Therapy with JAK2 inhibitors for myeloproliferative neoplasms. Hematol Oncol Clin North Am 2012;26(5):1083-99
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012;366(9):799-807
   PubMed Web of Science ®Google Scholar
• Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012;366(9):787-98
   PubMed Web of Science ®Google Scholar
• Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011;29(10):1356-63
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010;363(12):1117-27
   PubMed Web of Science ®Google Scholar
• Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc 2011;86(12):1188-91
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC. Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Rev Hematol 2014;7(2):203-16
   PubMed Web of Science ®Google Scholar
• Hind K, Burrows M. Weight-bearing exercise and bone mineral accrual in children and adolescents: a review of controlled trials. Bone 2007;40(1):14-27
   PubMed Web of Science ®Google Scholar
• Cooper C, Wickham C, Coggon D. Sedentary work in middle life and fracture of the proximal femur. Br J Ind Med 1990;47(1):69-70
   PubMedGoogle Scholar
• Tang BM, Eslick GD, Nowson C, et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370(9588):657-66
   PubMed Web of Science ®Google Scholar
• Bischoff HA, Stahelin HB, Urscheler N, et al. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 1999;80(1):54-8
   PubMed Web of Science ®Google Scholar
• Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer 2007;109(1):68-76
   PubMed Web of Science ®Google Scholar
• Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 2003;362(9384):640-50
   PubMed Web of Science ®Google Scholar
• Graves LIII, Stechschulte DJ, Morris DC, Lukert BP. Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. J Bone Miner Res 1990;5(11):1113-19
   PubMed Web of Science ®Google Scholar
• Hernlund E, Svedbom A, Ivergard M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013;8(1-2):136
   PubMed Web of Science ®Google Scholar
• Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19(8):1250-8
   PubMed Web of Science ®Google Scholar
• Garnero P, Shih WJ, Gineyts E, et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79(6):1693-700
   PubMed Web of Science ®Google Scholar
• Marshall A, Kavanagh RT, Crisp AJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol 1997;36(3):393-6
   PubMedGoogle Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 2000;85(11):4118-24
   PubMed Web of Science ®Google Scholar
• Benucci M, Bettazzi C, Bracci S, et al. Systemic mastocytosis with skeletal involvement: a case report and review of the literature. Clin Cases Miner Bone Metabol 2009;6(1):66-70
   PubMedGoogle Scholar
• Brumsen C, Hamdy NA, Papapoulos SE. Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 2002;17(4):567-9
   PubMed Web of Science ®Google Scholar
• Laroche M, Bret J, Brouchet A, Mazieres B. Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis. Clin Rheumatol 2007;26(2):242-3
   PubMed Web of Science ®Google Scholar
• Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002;20(15):3219-24
   PubMed Web of Science ®Google Scholar
• Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 2003;18(11):1947-54
   PubMed Web of Science ®Google Scholar